OBJECTIVE: Persons with diabetic retinopathy (DR) have an increased risk of clinical cardiovascular events. This study aimed to determine whether DR is associated with a range of measures of subclinical cardiovascular disease (CVD) in persons without clinical CVD. DESIGN: Population-based, cross-sectional epidemiologic study. PARTICIPANTS: Nine hundred twenty-seven persons with diabetes without clinical CVD in the Multi-Ethnic Study of Atherosclerosis. METHODS: Diabetic retinopathy was ascertained from retinal photographs according to modification of the Airlie House Classification system. Vision-threatening DR (VTDR) was defined as severe nonproliferative DR, proliferative DR, or clinically significant macular edema. Subclinical CVD measures were assessed and defined as follows: high coronary artery calcium (CAC) score, defined as CAC score of 400 or more; low ankle-brachial index (ABI), defined as ABI of less than 0.9; high ABI, defined as ABI of 1.4 or more; high carotid intima-media thickness (IMT), defined as highest 25% of IMT; and carotid stenosis, defined as more than 25% stenosis or presence of carotid plaque. MAIN OUTCOME MEASURES: Associations between DR and subclinical CVD measures. RESULTS: The prevalence of DR and VTDR in this sample was 30.0% and 7.2%, respectively, and VTDR was associated with a high CAC score (odds ratio [OR], 2.33; 95% confidence interval [CI], 1.15-4.73), low ABI (OR, 2.54; 95% CI, 1.08-5.99), and high ABI (OR, 12.6; 95% CI, 1.14-140.6) after adjusting for risk factors including hemoglobin A1c level and duration of diabetes. The association between VTDR and high CAC score remained significant after further adjustment for hypoglycemic, antihypertensive, and cholesterol-lowering medications. Diabetic retinopathy was not significantly associated with measures of carotid artery disease. CONCLUSIONS: In persons with diabetes without a history of clinical CVD, the presence of advanced-stage DR is associated with subclinical coronary artery disease. These findings emphasize the need to be careful about the use of anti-vascular endothelial growth factor for the treatment of DR.
OBJECTIVE:Persons with diabetic retinopathy (DR) have an increased risk of clinical cardiovascular events. This study aimed to determine whether DR is associated with a range of measures of subclinical cardiovascular disease (CVD) in persons without clinical CVD. DESIGN: Population-based, cross-sectional epidemiologic study. PARTICIPANTS: Nine hundred twenty-seven persons with diabetes without clinical CVD in the Multi-Ethnic Study of Atherosclerosis. METHODS:Diabetic retinopathy was ascertained from retinal photographs according to modification of the Airlie House Classification system. Vision-threatening DR (VTDR) was defined as severe nonproliferative DR, proliferative DR, or clinically significant macular edema. Subclinical CVD measures were assessed and defined as follows: high coronary artery calcium (CAC) score, defined as CAC score of 400 or more; low ankle-brachial index (ABI), defined as ABI of less than 0.9; high ABI, defined as ABI of 1.4 or more; high carotid intima-media thickness (IMT), defined as highest 25% of IMT; and carotid stenosis, defined as more than 25% stenosis or presence of carotid plaque. MAIN OUTCOME MEASURES: Associations between DR and subclinical CVD measures. RESULTS: The prevalence of DR and VTDR in this sample was 30.0% and 7.2%, respectively, and VTDR was associated with a high CAC score (odds ratio [OR], 2.33; 95% confidence interval [CI], 1.15-4.73), low ABI (OR, 2.54; 95% CI, 1.08-5.99), and high ABI (OR, 12.6; 95% CI, 1.14-140.6) after adjusting for risk factors including hemoglobin A1c level and duration of diabetes. The association between VTDR and high CAC score remained significant after further adjustment for hypoglycemic, antihypertensive, and cholesterol-lowering medications. Diabetic retinopathy was not significantly associated with measures of carotid artery disease. CONCLUSIONS: In persons with diabetes without a history of clinical CVD, the presence of advanced-stage DR is associated with subclinical coronary artery disease. These findings emphasize the need to be careful about the use of anti-vascular endothelial growth factor for the treatment of DR.
Authors: Ronit Katz; Nathan D Wong; Richard Kronmal; Junichiro Takasu; David M Shavelle; Jeffrey L Probstfield; Alain G Bertoni; Matthew J Budoff; Kevin D O'Brien Journal: Circulation Date: 2006-04-24 Impact factor: 29.690
Authors: Ronald Klein; Emily K Marino; Lewis H Kuller; Joseph F Polak; Russell P Tracy; John S Gottdiener; Gregory L Burke; Larry D Hubbard; Robin Boineau Journal: Br J Ophthalmol Date: 2002-01 Impact factor: 4.638
Authors: Ronald Klein; A Richey Sharrett; Barbara E K Klein; Scot E Moss; Aaron R Folsom; Tien Y Wong; Frederick L Brancati; Larry D Hubbard; David Couper Journal: Ophthalmology Date: 2002-07 Impact factor: 12.079
Authors: Tien Yin Wong; Ronald Klein; F M Amirul Islam; Mary Frances Cotch; Aaron R Folsom; Barbara E K Klein; A Richey Sharrett; Steven Shea Journal: Am J Ophthalmol Date: 2006-03 Impact factor: 5.258
Authors: Lucia Sobrin; Todd Green; Xueling Sim; Richard A Jensen; E Shyong Tai; Wan Ting Tay; Jie Jin Wang; Paul Mitchell; Niina Sandholm; Yiyuan Liu; Kustaa Hietala; Sudha K Iyengar; Matthew Brooks; Monika Buraczynska; Natalie Van Zuydam; Albert V Smith; Vilmundur Gudnason; Alex S F Doney; Andrew D Morris; Graham P Leese; Colin N A Palmer; Anand Swaroop; Herman A Taylor; James G Wilson; Alan Penman; Ching J Chen; Per-Henrik Groop; Seang-Mei Saw; Tin Aung; Barbara E Klein; Jerome I Rotter; David S Siscovick; Mary Frances Cotch; Ronald Klein; Mark J Daly; Tien Y Wong Journal: Invest Ophthalmol Vis Sci Date: 2011-09-29 Impact factor: 4.799